HERV-W

GeNeuro and Verily Collaborate to Advance Long-COVID Research

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, General Health, Pharmaceutical, Health, Biomarker, SARS-CoV-2, Verily, Workbench, Research, Environment, Euronext Paris, Disease, COVID, COVID-19, Molecular physics, Serum, Cell Press, Lymphocyte, Patient, HERV-W, Vaccine

Through this collaboration, GeNeuro will partner with Verily to build on results published earlier this year in Cell Press , which evidenced the in vitro activation of HERV-W by SARS-CoV-2 in susceptible individuals and the correlation between W-ENV protein levels in serum and lymphocytes with COVID-19 severity.

Key Points: 
  • Through this collaboration, GeNeuro will partner with Verily to build on results published earlier this year in Cell Press , which evidenced the in vitro activation of HERV-W by SARS-CoV-2 in susceptible individuals and the correlation between W-ENV protein levels in serum and lymphocytes with COVID-19 severity.
  • “Our research indicates that W-ENV contributes to COVID-19 disease severity and may explain manifestations of long-COVID,” said Dr. Hervé Perron, Chief Scientific Officer of GeNeuro.
  • Both solutions are part of Verily’s broader suite of products built to deliver on the promise of precision health and harness the power of richer, more diverse datasets to accelerate medical research.
  • “We are excited to partner with GeNeuro to advance our shared belief that identification of actionable biomarkers early in disease can advance precision health and save lives,” said Charlie Kim, Head of Molecular Science at Verily.

Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID

Retrieved on: 
Monday, December 13, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Other Health, Forward-looking statement, HERV-W, COVID, Technology, Symptoms of COVID-19, Company, FOPH, HIV disease progression rates, Severe acute respiratory syndrome coronavirus 2, Clinical trial, Euronext Paris, Genome, Brain, Public health, Association, Degenerative disease, Industry, Multiple sclerosis, COVID-19, Lancet, Rufus Herve Bacote, CEO, Swiss Federal Institute of Aquatic Science and Technology, Patient, Lymphocyte, Endothelium, Patent, Neurodegeneration, Alzheimer's disease, Blood, Long COVID, Pediatric acute-onset neuropsychiatric syndrome, Parkinson's disease, Lists of diseases, Pharmaceutical industry, Vaccine, Medical imaging, W-ENV and COVID-19, GeNeuro, W-ENV AND COVID-19, GENEURO

"We are extremely grateful for this funding from the FOPH, which will allow us to test GeNeuro's treatment for the neuropsychiatric forms of Long-COVID," said Jess Martin-Garcia, CEO of GeNeuro.

Key Points: 
  • "We are extremely grateful for this funding from the FOPH, which will allow us to test GeNeuro's treatment for the neuropsychiatric forms of Long-COVID," said Jess Martin-Garcia, CEO of GeNeuro.
  • Our approach is one of the first concrete leads to explain these problems, and also potentially to treat them with temelimab, GeNeuro's anti-W-ENV antibody."
  • This may allow early identification and treatment of patients who could benefit from anti-W-ENV therapy with temelimab.
  • Based in Geneva, Switzerland, and with an R&D center in Lyon, France, GeNeuro holds the rights to 17 patent families that protect its technology.

GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID

Retrieved on: 
Friday, September 24, 2021
Research, Genetics, Clinical Trials, Biotechnology, Health, University, Pharmaceutical, Science, Education, Blood, International Center, Northwestern University, Patent, Lists of diseases, Research, Endothelium, Degenerative disease, Euronext Paris, Pediatric acute-onset neuropsychiatric syndrome, HERV-W, DNA, Patient, COVID, Lymphocyte, Disease, Leadership, COVID-19, Technology, Northwestern Memorial Hospital, Rufus Herve Bacote, Severe acute respiratory syndrome coronavirus 2, Brain, Northwestern Medicine, CIRI, Neurodegeneration, Multiple sclerosis, Neuro, Pharmaceutical industry, Vaccine, Medical imaging, W-ENV and COVID-19, GeNeuro, W-ENV AND COVID-19, GENEURO

Northwestern University is a pioneer in the comprehensive treatment of long-haul COVID-19 symptomatology, having established a Neuro COVID-19 Clinic at Northwestern Memorial Hospital as early as May 2020.

Key Points: 
  • Northwestern University is a pioneer in the comprehensive treatment of long-haul COVID-19 symptomatology, having established a Neuro COVID-19 Clinic at Northwestern Memorial Hospital as early as May 2020.
  • The purpose of the research agreement is to establish evidence of W-ENV expression on the transcriptional and protein level, to ascertain whether this protein can be a blood biomarker of neurological complications of long-haul COVID.
  • This research agreement complements the previously announced efforts in the long-haul COVID field that GeNeuro has launched in Europe with Fondation FondaMental and the CIRI (International Center for Infectiology Research, Lyon, France).
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.